# Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer

> **NCT01118039** · PHASE2 · UNKNOWN · sponsor: **Hospital del Mar** · enrollment: 41 (estimated)

## Conditions studied

- Bladder Cancer
- Transitional Cell Cancer of the Renal Pelvis and Ureter
- Urethral Cancer

## Interventions

- **DRUG:** sunitinib malate
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT01118039
- **Lead sponsor:** Hospital del Mar
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-07
- **Primary completion:** 2010-12
- **Final completion:** —
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2013-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01118039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01118039, "Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT01118039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*